KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Abstract | PURPOSE: METHODS: RESULTS: Compared with patients with KRAS-wild-type tumors, patients with KRAS-mutated tumors did not experience any difference in disease-free, recurrence-free, or overall survival. The 5-year disease-free, recurrence-free, and overall survival rates (KRAS-mutated versus KRAS-wild-type patients) were 62% versus 63% (log-rank P = 0.89), 64% versus 66% (P = 0.84), and 75% versus 73% (P = 0.56), respectively. The effect of KRAS mutation on patient survival did not significantly differ according to clinical features, chemotherapy arm, or microsatellite instability status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status. CONCLUSIONS: In this large trial of chemotherapy in stage III colon cancer patients, KRAS mutational status was not associated with any significant influence on disease-free or overall survival.
|
Authors | Shuji Ogino, Jeffrey A Meyerhardt, Natsumi Irahara, Donna Niedzwiecki, Donna Hollis, Leonard B Saltz, Robert J Mayer, Paul Schaefer, Renaud Whittom, Alexander Hantel, Al B Benson 3rd, Richard M Goldberg, Monica M Bertagnolli, Charles S Fuchs, Cancer and Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research Institute, Southwest Oncology Group |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 23
Pg. 7322-9
(Dec 01 2009)
ISSN: 1557-3265 [Electronic] United States |
PMID | 19934290
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antineoplastic Agents
- Irinotecan
- Oncogene Protein p21(ras)
- Camptothecin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(pharmacology)
- Camptothecin
(analogs & derivatives, pharmacology)
- Colonic Neoplasms
(drug therapy, genetics, metabolism, surgery)
- Disease-Free Survival
- Female
- Genes, ras
- Humans
- Irinotecan
- Male
- Microsatellite Repeats
- Middle Aged
- Mutation
- Oncogene Protein p21(ras)
(genetics)
- Proportional Hazards Models
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|